<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A drug surveillance study was conducted, aimed at evaluating the efficacy and safety of nicardipine in outpatients with cerebrovascular diseases and at assessing the changes in nonfocal symptoms in the treated patients </plain></SENT>
<SENT sid="1" pm="."><plain>The 3,150 outpatients (mean age, 68.9 years) were being treated by general practitioners and neurologists in Barcelona, Spain </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">Cerebral embolism</z:e> was diagnosed in 4.0%, <z:hpo ids='HP_0005305'>cerebral thrombosis</z:hpo> in 13.0%, transitory ischemic attack in 28.0%, and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in 55.0% </plain></SENT>
<SENT sid="3" pm="."><plain>The daily dose of nicardipine ranged from 20 to 180 mg; 87.7% of the patients received 60 mg of nicardipine daily </plain></SENT>
<SENT sid="4" pm="."><plain>Concomitant medications were being taken by 89.1% of the patients </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment was evaluated in 2,913 patients </plain></SENT>
<SENT sid="6" pm="."><plain>After 60 days of treatment, marked improvement was noted in 31.0% of the patients, moderate improvement in 39.0%, slight improvement in 20.0%, and no change in 10.0% </plain></SENT>
<SENT sid="7" pm="."><plain>Marked or moderate improvement was noted in 69.6% of the patients who received nicardipine alone and in 66.9% of the patients who received concomitant medications </plain></SENT>
<SENT sid="8" pm="."><plain>Clinically significant drops in blood pressure during treatment were found in the hypertensive patients </plain></SENT>
<SENT sid="9" pm="."><plain>Side effects were reported by 14.5% of <z:hpo ids='HP_0000001'>all</z:hpo> patients and by 4.6% of the patients who received nicardipine alone </plain></SENT>
<SENT sid="10" pm="."><plain>It is concluded that the daily administration of nicardipine is safe and effective in outpatients with cerebrovascular disorders </plain></SENT>
</text></document>